<DOC>
	<DOCNO>NCT02455622</DOCNO>
	<brief_summary>This long-term study provide Elaprase treatment child enrol study utilize data enrol patient Hunter Outcome Survey ( HOS ) patient registry data conduct primary growth analysis ass change height weight patient Mucopolysaccharidosis II ( Hunter syndrome ) MPS II .</brief_summary>
	<brief_title>Long-term Evaluation Height Weight Patients With MPS II Who Started Treatment &lt; 6 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<criteria>Group 1 : Prospective Patient Group 1 . The patient male . 2 . The patient Elaprasenaïve study entry . 3 . The patient must document diagnosis MPS II . Of 3 criterion , combination ( 3a AND 3b ) ( 3a AND 3c ) accept diagnostic MPS II : 1 . The patient deficiency I2S enzyme activity ≤10 % low limit normal range measure plasma , fibroblast , leukocyte ( base reference laboratory 's normal range ) . AND 2 . The patient document mutation I2S gene . OR 3 . The patient normal enzyme activity level one sulfatase measure plasma , fibroblast , leukocyte ( base normal range measure laboratory ) . 4 . The patient &lt; 6 year age start Elaprase treatment . 5 . The patient , patient 's parent ( ) legally authorize guardian ( ) must voluntarily sign Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve informed consent form relevant aspect study explain discuss . Consent patient 's parent ( ) legally authorize guardian ( ) patient 's assent , relevant , must obtain . Group 2 : Retrospective Data Retrospective Patient Group patient enrol HOS Study SHPELA401 ; however , growth data may include analysis Study SHPELA401 follow data inclusion criterion meet . 1 . The patient male . 2 . The patient enrol HOS . 3 . The patient &lt; 6 year age start Elaprase treatment . 4 . The patient receive Elaprase weekly treatment least 5 year . 5 . The patient height assessment weight assessment document within 3 month Elaprase treatment start . 6 . The patient annual height weight assessment start Elaprase age 10 year . 7 . The patient , patient 's parent ( ) , legally authorize guardian ( ) agree ( ) data collection . 8 . The patient , patient 's parent ( ) , legally authorize guardian ( ) must sign IRB/IECapproved informed consent form relevant aspect HOS study explain discuss . Consent patient 's parent ( ) legally authorize guardian ( ) patient 's assent , relevant , must obtain . Group 1 : Prospective Patient Group 1 . The patient receive treatment investigational drug device within 30 day prior study entry . 2 . The patient receive receive treatment idursulfaseIT . 3 . The patient receive growth hormone , cord blood infusion , bone marrow transplant time . 4 . The patient receive blood product transfusion within 90 day prior Screening . 5 . The patient unable comply protocol determine Investigator . Group 2 : Retrospective Data HOS patient meet follow criterion eligible include Study SHPELA401 Primary Growth Analysis : 1 . Patient treat growth hormone medication intervention intend promote growth time period cover analysis .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>